Molecular markers are required to refine prediction of recurrence risk for colorectal cancer to help guide management for individual patients. In this comprehensive study of oncogene mutations in colorectal cancer metastases from different sites, we provide evidence that KRAS mutation in the primary tumor is associated with an increased risk of metastasis in the lung and brain, but does not modify the risk of metastasis in the liver. Our data highlight the potential of somatic mutations for informing surveillance strategies and has implications for understanding metastatic progression in colorectal cancer. Oncogene mutations contribute to colorectal cancer development. We searched for differences in oncogene mutation profiles between colorectal cancer metastases from different sites and evaluated these as markers for site of relapse.
INTRODUCTION
Approximately 20% of colorectal cancer patients present with distant metastasis, and about one third of patients undergoing curative-intent surgery for primary cancer will relapse at distant sites (1) . Relapse often occurs within three years, with distant recurrence commonly found in the liver, lung and peritoneum (2) (3) (4) . Given this pattern, surveillance of the abdomen and chest is recommended, though the optimal strategy remains uncertain (5, 6) .
Activating mutations in oncogenes contribute to carcinogenesis, and over 20 oncogenes have been identified in human solid malignancies (7) . In colorectal cancer, oncogenic mutations are commonly found in the mitogen activated kinase (MAPK) pathway members BRAF (~10%) (8, 9) , KRAS (~40%) (10, 11) and NRAS (~3%) (12, 13) , and the phosphatidylinositol 3-kinase (PI3K) pathway member PIK3CA (~20%) (14, 15) . Recent studies have shown that patients with metastatic colorectal cancer harboring KRAS mutation do not benefit from therapy with monoclonal antibodies against the epidermal growth factor receptor (EGFR) (16) (17) (18) , and BRAF and PIK3CA mutations may similarly confer resistance to such treatment (19) (20) (21) (22) , although this remains controversial (23) .
Recurrence patterns are partly determined by patient characteristics such as primary tumor location (2-4), but whether the somatic mutation profile of the primary tumor influences site of relapse remains unknown. There is limited data suggesting that KRAS mutation prevalence may differ between colorectal cancer metastases from the liver (32%) and lung (58%), and between primary cancers from patients with synchronous or metachronous liver (35%) Author Manuscript Published OnlineFirst on January 14, 2011; DOI: 10.1158/1078-0432.CCR- and lung metastases (57%) (24) . However, another study of resected liver and lung metastases reported similar KRAS mutation frequencies (50.0% vs.
43.5%) (25).
The OncoCarta™ Panel v1.0 from Sequenom allows for high-throughput screening of 238 pathogenic mutations in 19 oncogenes. We applied this technology to search for differences in oncogene mutation profiles between colorectal cancer metastases from the liver (n=65), lung (n=50) and brain (n=46) (cohort A), and compared site-specific mutation frequencies with those observed in a clinic-based cohort of 604 independent primary tumours (cohort B). Mutations with differential frequencies between metastasis sites were evaluated as markers for site of relapse in 859 patients from the VICTOR trial (VIOXX in colorectal cancer therapy: definition of optimal regime; cohort C), a Phase III study of rofecoxib (VIOXX®) (26) . A third set of primary colorectal cancers were retrieved from 859 stage II and III patients participating in the VICTOR clinical trial (cohort C) (26) . All patients had undergone curative-intent surgery, and none had shown evidence of distant metastases at the time of surgery.
MATERIALS AND METHODS

Patients
DNA Extraction
Formalin-fixed paraffin-embedded tumor and normal tissues were retrieved and macrodissected from serial sections following histological review, with tumor areas comprising greater than 60% neoplastic cells. Genomic DNA was extracted using the DNAeasy Blood & Tissue DNA Isolation Kit (QIAGEN).
Oncogene Mutation Profiling
The OncoCarta™ Panel v1.0 and MassArray System from Sequenom (San Diego, CA) were used to assay 238 pathogenic mutations in 19 oncogenes. All detected mutations were validated by bi-directional DNA sequencing from new PCR product. DNA sequencing reactions were performed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA), and samples were analyzed on an ABI 3130xl or 3730xl
Genetic Analyzer (Applied Biosystems).
BRAF, KRAS, NRAS and PIK3CA Mutation Determination
Research. 
MSI Determination
Microsatellite instability (MSI) status was determined by analysis of paired normal and tumor DNA samples using the Bethesda panel of five microsatellite markers (27) . Fluorescently-labeled PCR products were run on an ABI 3130xl Genetic Analyzer and the data analyzed with GeneMapper Software Version 4.0. A tumor was classified as microsatellite unstable if two or more of the five loci showed instability.
Statistical Analysis
Statistical analyses were conducted using R software (28) . Differences between groups were assessed using Fisher's exact test for categorical proportional-hazards models were used to estimate survival distributions and hazard ratios, and were adjusted for patient characteristics and MSI status as indicted. All statistical analyses were two-sided and considered significant if
P<0.05.
RESULTS
Oncogene Mutation Profile of Colorectal Cancer Metastases (Cohort A)
Oncogene mutations were surveyed in 161 metastases (65 liver, 50 lung and 46 brain) from 148 colorectal cancer patients (cohort A, Table 1 Table 2 , available online). 63.4% (102/161) of cases had mutation in at least one of these oncogenes and 11.2% (18/161) had mutations in more than one oncogene.
Mutations in the MAPK pathway members KRAS, NRAS and BRAF were mutually exclusive (P<0.001, log-linear analysis). PIK3CA mutations co-existed with KRAS (15 cases) and NRAS (3 cases) mutations, but were not found with BRAF mutations; these findings were as expected from independent mutations (P>0.20 for all pairwise comparisons, Fisher's exact test). For the 12 persons for whom two or more metastases were tested, mutation status was concordant.
Differences in Oncogene Mutation Spectra Between Colorectal Cancer
Metastases from Different Sites (Cohort A)
Frequencies of BRAF, KRAS, NRAS, and PIK3CA mutations were compared between metastases from the liver, lung and brain (cohort A, Table   2 ). KRAS and PIK3CA mutation frequencies were found to vary significantly across these sites (P=0.003 and P=0.044, respectively; Fisher's exact test). For both genes, mutation frequencies were higher in lung and brain metastases as mutations with respect to metastasis site, although the number of mutant cases was small for both genes. BRAF mutation was detected in 0% (0/50) of lung, 6.5% (3/46) of brain and 3.1% (2/65) of liver metastases; NRAS mutation was found in 6.0% (3/50) of lung, 4.3% (2/46) of brain and 7.7% (5/65) of liver metastases.
To assess whether the associations between KRAS or PIK3CA mutation status and metastasis site were independent of patient characteristics, multivariate logistic regression analyses were performed including age at surgery, gender and primary cancer location ( Table 3 ). The association between metastasis site and KRAS mutation status remained significant, but the association for PIK3CA status no longer reached statistical significance.
Concordance of Oncogene Mutation Status Between Paired Primary
Cancers and Metastases (Cohort A)
To assess whether oncogene mutations observed in metastases were acquired prior or post distant spread, we analyzed the matched primary cancers that were available for 87 of 148 patients (cohort A, Supplementary 
Differences in KRAS Mutation Frequencies Between Colorectal Cancer
Metastases (Cohort A) and Independent Primary Cancers (Cohort B)
The association between KRAS mutation and metastasis site together with the high concordance of mutation status in primary and metastatic tumor indicate a potential for KRAS mutation in predicting site of relapse following surgery for primary cancer. To further investigate this suggestion, KRAS mutation frequencies in liver, lung and brain metastases (cohort A) were compared to the baseline prevalence in 604 primary cancers from an independent, clinic-based patient cohort (cohort B, Table 1 ). Compared to a prevalence of 34.9% (211/604) in independent primary cancers, KRAS mutation frequency was similar in liver metastases (32.3%, P=0.784, Fisher's exact test), but significantly higher in lung (62.0%) and brain (56.5%) metastases (P<0.001 and P=0.004, respectively; Fisher's exact test) ( Table 4) . Taken together these data suggest that KRAS mutation in the primary tumor may be associated with an increased risk of relapse in the lung or brain, but may not modify the risk of relapse in the liver.
KRAS Mutation Status is Associated with Relapse in the Lung (Cohort C)
To formally evaluate KRAS mutation status as a marker for specific sites of relapse, we analyzed primary colorectal cancers from 859 stage II and III patients participating in the VICTOR clinical trial (cohort C, Patients in this study were followed up three and six months after study entry, then every six months up to two years, and annually thereafter. Radiological evidence or positive biopsy was required to demonstrate recurrence, and data on first site(s) of relapse was systematically recorded. The median follow-up time was 58.5 months (range 4.8-100.0 months). Of 198 individuals who experienced disease recurrence, 68 had confirmed relapse in the liver and 55 confirmed relapse in the lung; 12 of these individuals relapsed in both sites.
Relapse in the brain was not evaluated as cerebral imaging was not performed as part of routine follow-up.
KRAS mutations were identified in 290 of 859 (33.8%) primary cancers, and liver or lung relapse-free survival rates of patients were compared by mutation status (Figure 1 A-B) . As anticipated from our comparison of KRAS mutation frequencies between metastases and independent primary cancers, the presence of KRAS mutation in patients from the VICTOR study was not associated with relapse in the liver (HR 0.9; 95% CI, 0.6-1.6; P=0.837, Wald test), but was significantly associated with relapse in the lung with an estimated hazard ratio of 2.1 for individuals with KRAS mutant as compared to KRAS wild-type cancers (95% CI 1.2-3.5, P=0.007, Wald test). A similar result for lung relapse was obtained in multivariate analysis (Table 5) Table 4 , available online).
The differential impact of KRAS mutation on site-specific relapse was further evident when comparing lung and liver relapse-free survival for patients stratified by mutation status (Figure 1 C-D confirming that mutation testing of primary tumor is a reasonable surrogate for treatment decisions in metastatic disease.
In our comparison of oncogene mutation profiles between colorectal cancer metastases from different sites, KRAS mutations were significantly more common in lung (62%) and brain metastases (56%) as compared to liver metastases (32%), adjusting for patient clinicopathological characteristics. A similar trend for PIK3CA mutation status did not reach statistical significance in multivariate analysis. The prevalence of KRAS mutations in our resected liver metastases was consistent with the 27% to 39% reported in previous series of between 62 and 188 patients (32, 35, 36) . Less robust data are available for lung metastases, with KRAS mutation frequencies of 44% and 59% for two small cohorts of 23 and 17 cases, respectively (24, 25) . To our knowledge, this study is the first to report comprehensive oncogene mutation data for colorectal cancer metastases to the brain.
Compared to the baseline KRAS mutation prevalence of 35% observed in a large cohort of independent primary cancers, KRAS mutations were significantly more common in lung and brain metastases, but similar in liver metastases. As anticipated from this data, the presence of KRAS mutation was found to be significantly associated with lung relapse, but not liver relapse, in patients from the VICTOR trial in both univariate and multivariate analyses. 
oligo-metastatic disease may produce survival benefits in suitable candidates (46) (47) (48) . Our data suggest that KRAS mutation status may identify patients at increased risk of recurrence in the brain, but studies on larger patient cohorts will be required to formally demonstrate this association.
In conclusion, our findings provide evidence that recurrence patterns in colorectal cancer patients are partly determined by the somatic mutation profile of the primary tumor. This data has implications for understanding metastatic progression in colorectal cancer, and may help inform surveillance strategies for patients undergoing surgery with curative intent. Table 5 . Multivariate hazard ratios from Cox proportional hazards regression models of KRAS mutation status and relapse-free survival for colorectal cancer recurrence to the liver or lung, adjusting for patient characteristics (n = 859 patients participating in the VICTOR clinical trial; cohort C). 
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